Abstract: A process for the preparation of 14-alkoxyindolomorphinans and 14-alkoxybenzofuranomorphinans is disclosed. The process facilitates the preparation of a large variety of 14-alkoxy substituted indolomorphinans and benzofuranomorphinans in which a 3-hydroxy substituent is present.

Abstract: The present invention relates to monoclonal antibodies which recognize defined regions of the T-cell receptor (TCR). In a specific embodiment, the invention provides monoclonal antibodies which are reactive with a constant region of the alpha chain of the TCR. In particular embodiments, the invention relates to two monoclonal antibodies, termed .alpha.F1 and .alpha.F2, which react with two different epitopes on the framework region of the .alpha. monomer of the TCR molecule. In another specific embodiment, the invention is directed to monoclonal antibodies reactive with a variable region of the beta chain of the TCR. In particular, the invention provides two monoclonal antibodies, termed W112 and 2D1, which react with .beta. chain variable regions V.beta.5.3 and V.beta.8.1, respectively. In another specific embodiment, the invention is directed to monoclonal antibodies reactive with a variable region of the delta chain of the TCR. In particular, the invention provides monoclonal antibody .delta.

Abstract: The present invention relates to monoclonal antibodies which recognize defined regions of the T-cell receptor (TCR). In a specific embodiment, the invention provides monoclonal antibodies which are reactive with a constant region of the alpha chain of the TCR. In particular embodiments, the invention relates to two monoclonal antibodies, termed .alpha.F1 and .alpha.F2, which react with two different epitopes on the framework region of the .alpha. monomer of the TCR molecule. In another specific embodiment, the invention is directed to monoclonal antibodies reactive with a variable region of the beta chain of the TCR. In particular, the invention provides two monoclonal antibodies, termed W112 and 2D1, which react with .beta. chain variable regions V.beta.5.3 and V.beta.8.1, respectively. In another specific embodiment, the invention is directed to monoclonal antibodies reactive with a variable region of the delta chain of the TCR. In particular, the invention provides monoclonal antibody .delta.

Abstract: New compounds of the formula (A) ##STR1## a process for their preparation and their use in the manufacture of pharmaceutical preparations. The new compounds have both local anaesthetic and analgesic effect.

Abstract: There is provided compounds of formula I,R.sup.1 O(O)C--CH.sub.2 --(R)Cgl-Aze-Pab-R.sup.2 Iwherein R.sup.1 and R.sup.2 have meanings given in the description, which are useful as prodrugs of inhibitors of trypsin-like proteases, such as thrombin, and in particular in the treatment of conditions where inhibition of thrombin is required (eg thrombosis) or as anticoagulants.

Abstract: The present invention relates to a pump chamber (1) for a pump intended primarily for infusion systems for medical use, said pump chamber comprising walls (21, 28) delimiting said chamber and an inlet (22) and an outlet (23), a part of said walls of said pump chamber being formed by a flexible membrane (40, 90), said membrane being actuatable by a reciprocally movable actuating means (80), thus varying the volume of the pump chamber in accordance with the movements of said actuating means. The membrane (40, 90) has a convex domed shape projecting outwardly from said pump chamber (1) and is made of a resiliently flexible material, the apex of the domed membrane being acted upon by said actuating means, said actuating means having a stroke which may be adjusted to the amount of the dose to be administered. The invention also relates to a valve for a pump chamber.

Abstract: The invention relates to a process for the production of enantiomerically-pure AzeOH which comprises selective crystallisation of a diastereomerically-pure tartrate salt thereof, followed by liberation of the free amino acid, as well as the compounds L-azetidine-2-carboxylic acid-D-tartrate and D-azetidine-2-carboxylic acid-L-tartrate.

Abstract: A new pharmaceutical preparation comprising one or more local anaesthetic agents, a polar lipid, a triacylglycerol and optionally water. The new pharmaceutical preparation is excellent for topical treatment of pain.

Abstract: New combination of a .beta.-receptor blocker or a pharmaceutically acceptable salt thereof, and an opioid or a pharmaceutically acceptable salt thereof, optionally in the presence of a pharmaceutically acceptable carrier or any additional agents which may be active or inactive. The new combination confers a synergistic effect, and provides unexpected efficacy in the treatment of pain.

Abstract: There are provided new compounds of formula I: ##STR1## wherein R represents hydrogen or methyl; andn represents 1 or 2;or a pharmaceutically acceptable acid addition salt thereof, together with processes for preparing them, compositions containing them and their use in therapy. Compounds of formula I are expected to be useful in the treatment of psychotic disorders, intellectual impairment disorders and anxiety.

Abstract: New morphinane derivatives of the formula (I) ##STR1## their pharmaceutically acceptable salts, a process for their preparation and their use in therapy. The variables in the above structure are as follows: R.sub.1 is selected from the group consisting of C.sub.1 -C.sub.6 alkyl and hydrogen;R.sub.2 is selected from the group consisting of hydrogen; hydroxy; C.sub.1 -C.sub.6 alkoxy; C.sub.7 -C.sub.16 arylalkyloxy, wherein the aryl is C.sub.6 -C.sub.10 aryl and the alkyloxy is C.sub.1 -C.sub.6 alkyloxy;R.sub.3 is a C.sub.1 -C.sub.6 alkyl;R.sub.4 is a hydrogen; hydroxy; or a C.sub.1 -C.sub.6 alkoxy;R.sub.5 and R.sub.6 each and independently are selected from the group consisting of hydrogen; and C.sub.1 -C.sub.6 alkyl;X is NR.sub.9, wherein R.sub.9 is selected from the group consisting of hydrogen; and C.sub.1 -C.sub.6 alkyl;and wherein any aryl group in the compound may be unsubstituted or mono-, di-, or tri-substituted independently with hydroxy; halo; nitro; cyano; thiocyanato; trifluoromethyl; C.sub.1 -C.

Abstract: The present invention relates to humanized antibodies and binding proteins thereof, capable of binding to T cells exhibiting particular variable beta chains, and particularly those subpopulations expressing human V beta 5.2 and/or 5.3, and V beta 8.1. The present invention also relates to the preparation of such antibodies, to pharmaceutical compositions containing them, and therapeutic utilization of the antibodies, specifically in autoimmune diseases.

Abstract: New combination of a .beta.-receptor blocker, an enantiomer thereof, and a local anesthetic, administered simultaneously or sequentially, giving excellent pain relief. Also comprised in the invention is the use of a non-selective .beta.-receptor blocker alone, especially a non-selective .beta.-receptor blocker giving pain relief.

Abstract: An apparatus for administering a fluid medicament to a patient in a gas for inhalation and for calculating the dosage administered to the patient comprising a holding member (1) for temporarily holding the medicament and gas prior to inhalation, means for introducing a quantity of the medicament into the holding chamber (1), a sensor (4) for detecting the introduction of the medicament into the holding chamber (1), detector means for detecting the rate of flow of gas inhaled by a patient from the holding chamber (1) and calculation means (25, 27, 29, 30, 31) operably connected to the sensor (4) and to the detector means for calculating the amount of medicament received by a patient.

Abstract: Compounds of the formula I ##STR1## as well as methods for their preparation, their pharmaceutical preparations and their use in therapy, especially as analgesics and as immunosuppressive agents.

Abstract: Compounds of the formula I as well as methods for their preparation, their pharmaceutical preparations and their use as analgesics.

Abstract: A topical dressing for dermal or transdermal administration of a substance, comprising a backing structure comprising a disc, a pad containing the active substance, a resilient layer with an adhesive provided on one side thereof, the resilient layer and the adhesive being provided with a cut-out defining a cavity in which the pad is placed, the disc of the backing structure being provided on the side of the resilient layer remote from the side provided with the adhesive and partly covering the resilient layer, and a covering structure having a release layer and a dish, the dish being formed to receive the pad during production and storage of the dressing, said covering structure being provided on the adhesive side of the resilient layer, whereby the backing structure is provided with one or more strips extending outwardly from the periphery edge of the backing disc towards the periphery edges of the resilient layer and in that the cover structure and the backing structure are sealed together within the cavity

Abstract: The invention is directed to monoclonal antibodies reactive with a member of the V.beta.3 family variable region of the beta chain of the TCR. More particularly, the invention provides for detection of the V.beta.3.1 subfamily. In a specific embodiment the invention provides for detection of V.beta.3.1, without cross-reacting with other V.beta.3 family variable regions. In a specific embodiment, the monoclonal antibodies of the invention do not react with V.beta.3.2. In particular, the invention provides monoclonal antibodies, termed 5E4 and 8F10, which react with the variable region of a member of the V.beta.3 family. In various embodiments of the invention, these antibodies, or fragments or derivatives thereof, can be used to bind with a member of the V.beta.3 family TCR variable region amino acid sequences, either as part of an intact TCR or peptide, or T cell-surface molecule, or a fragment thereof.

Abstract: The present invention discloses a new and improved process for the preparation of sameridine and its pharmaceutically acceptable salt.